Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

RXi Pharmaceuticals Corp RXII

"RXi Pharmaceuticals Corp is a clinical-stage RNAi company developing therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which address significant unmet medical needs."


NDAQ:RXII - Post by User

Post by mersoleil11on May 06, 2015 8:35am
66 Views
Post# 23698666

Price target 5 $

Price target 5 $Analysts at HC Wainright lowered their price target on shares of RXi Pharmaceuticals Corp from $9.00 to $5.00 and set a buy rating on the stock in a research note on Tuesday, March 31st. They noted that the move was a valuation call.
https://www.wkrb13.com/markets/579238/rxi-pharmaceuticals-corp-given-buy-rating-at-zacks-rxii/
<< Previous
Bullboard Posts
Next >>